Analysts' Actions: AIG, DOW, EZPW, FOSL
NEW YORK (TheStreet) -- CHANGE IN RATINGS
Aetna(AET) was downgraded from Neutral to Sell at Goldman Sachs. Commercial margins could continue to fall, Goldman said. $45 price target.
AIG(AIG) was upgraded to Buy at Goldman Sachs. Chart is is showing progress, and the company has multiple potential catalysts, Goldman said. $40 price target.
CF Industries(CF) was downgraded at Dahlman Rose. Higher corn supplies could weigh on prices, Dahlman Rose said. $155 price target.
Dish(DISH) was downgraded to Hold at TheStreet Ratings.
Dow Chemical(DOW) was upgraded at Morgan Stanley from Equal-Weight to Overweight. $38 price target. Company should benefit from lower ethane prices, Morgan Stanley said.
EZCorp(EZPW) was upgraded at Sterne Agee from Underperform to Neutral. Valuation call, based on a $24 price target, Sterne Agee said.
Fossil(FOSL) was upgraded at Benchmark from Hold to Buy. $100 price target. Estimates also cut, given lower expected sales in Europe, Benchmark said.
Fossil was downgraded at JP Morgan from Overweight to Neutral. Company's growth story is in transition, JP Morgan said. $88 price target.
Generac Holdings(GNRC) was downgraded at Goldman Sachs to Neutral from Buy. $30 price target. Risk reward around consensus estimates is now balanced, Goldman said.
Global Partners (GLP) was downgraded to Hold at TheStreet Ratings.
Herbalife(NOK) was downgraded at Caris & Co. from Buy to Average. $39 price target. Expect David Einhorn to weigh on sentiment, Caris said.
Hershey(HSY) was upgraded at Argus from Hold to Buy. $78 price target. Company is realizing higher sales growth, Argus said.
Humana(HUM) was downgraded at Goldman Sachs from Buy to Neutral. Valuation call, based on a $90 price target, Goldman said.
Immunomedics (IMMU) was downgraded to Hold at TheStreet Ratings.
Jive Software(JIVE) was initiated with a Hold rating at Needham. Valuation call, Needham said.
Janus Capital(JNS) was upgraded at Bank of America/Merrill Lynch from Underperform to Neutral. Valuation call, based on an $8.50 price target, Bank of America/Merrill Lynch said.